Cancer





About Mediscience Detection
History
Strategy
Business
Technical
product
clinical
Cancer

RESEARCH & DEVELOPMENT

Research & Product Development

Clinical Development

Research & Product Development

The potential utility of native tissue fluorescence spectroscopy for in vivo cancer detection in humans was first discovered by Professor Robert R. Alfano, Distinguished Professor of Physics and Engineering at the City College of the City University of New York ("CUNY") in the early 1980's. Subsequent to the acquisition by the Company of LDI from Dr. Alfano in 1988, we developed a research agreement with the Research Foundation of CUNY to provide us with research and development services. In 1992, the Company, CUNY, and the Research Foundation of CUNY established the Mediphotonics Laboratory ("MPL") at the City College of New York to provide research and development services in the area of tissue spectroscopy and cancer detection and other biological applications. The staff of MPL, which is supervised by Dr. Alfano, developed our current CD prototype devices. MPL has also conducted in vitro, pre-clinical testing of various human tissue types such as breast, cervical, colon and the upper aerodigestive tract, to develop the preferred optical scanning and emission wavelengths that yield the most definitive information about the native fluorescence characteristics of specific scanned tissue. The insight gained from this work has been the principal source of knowledge for the subsequently issued and pending patents which the Company either owns outright or for which it possesses a world wide exclusive license, and which the Company regards as pioneering, blocking and dominant in the area of cancer diagnosis using fluorescence. The information derived from this work was also the source for a number of scientific papers published in peer-review journals and for presentations made at scientific symposia. This in-vitro preclinical research and development work also provided the starting basis for the optical scanning parameters for the Company's in vivo human clinical studies.

top of page


Clinical Development

The development of our CD products are designed primarily to be used directly on human patients in-vivo. Part of the process of product development and FDA approval is the development of sufficiently compelling clinical evidence to demonstrate safety and effectiveness of one or more of the Company's prototype CD products for each intended diagnostic application (labeled or intended use). Because of the anticipated clinical utility of our technology and prototype CD products, we have been able to develop important collaborative relationships with some of the most highly regarded cancer center research hospitals in the United States to assist in the clinical evaluation of our prototype products. These institutions include Memorial Sloan-Kettering Cancer Center, Columbia Presbyterian Hospital and the New York Hospital (Cornell Medical Center), each of New York, and the Massachusetts General Hospital (Harvard Medical School) in Boston.

top of page